ArticleMicrobial cell factories2018
Production of a human milk oligosaccharide 2'-fucosyllactose by metabolically engineered Saccharomyces cerevisiae.
Article in Microbial cell factories, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Programmable HMO biosynthesis enabled by human cell-based glycoengineering.Glycobiology · 2026Article
- Biosynthesis of human milk oligosaccharides (HMOs) in glycoengineered human cells.Glycobiology · 2026Article
- A comprehensive safety evaluation of approved 2'-fucosyllactose for human nutritional applications in China.Frontiers in toxicology · 2026Article
- Efficient production of 2'-fucosyllactose inSynthetic and systems biotechnology · 2025Article
- Optimization and semi-continuous fermentation of gluco-oligosaccharide production withFood science and biotechnology · 2025Article
- Intensification of 2'-Fucosyllactose biosynthesis pathway by using a novel fucosyltransferase fromFrontiers in bioengineering and biotechnology · 2025Article
- Enhancing the Techno-Functional Properties of Lentil Protein Isolate Dispersions Using In-Line High-Shear Rotor-Stator Mixing.Foods (Basel, Switzerland) · 2024Article
- Copper-Induced In Vivo Gene Amplification in Budding Yeast.Biodesign research · 2024Article
- Efficient production of 2'-fucosyllactose in unconventional yeastSynthetic and systems biotechnology · 2023Article
- Prebiotics in New-Born and Children's Health.Microorganisms · 2023Review
- Recent Advances in the Biosynthesis of Natural Sugar Substitutes in Yeast.Journal of fungi (Basel, Switzerland) · 2023Review
- Directed Evolution of Soluble α-1,2-Fucosyltransferase Using Kanamycin Resistance Protein as a Phenotypic Reporter for Efficient Production of 2'-Fucosyllactose.Journal of microbiology and biotechnology · 2022Article
- Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.Microbial cell factories · 2022Article
- Engineered Bacillus subtilis for the de novo production of 2'-fucosyllactose.Microbial cell factories · 2022Article
- Transporter Engineering in Microbial Cell Factory Boosts Biomanufacturing Capacity.Biodesign research · 2022Review
- Improved production of 2'-fucosyllactose in engineered Saccharomyces cerevisiae expressing a putative α-1, 2-fucosyltransferase from Bacillus cereus.Microbial cell factories · 2021Article
- Microbial production of human milk oligosaccharide lactodifucotetraose.Metabolic engineering · 2021Article
- Production of perdeuterated fucose from glyco-engineered bacteria.Glycobiology · 2021Article
- Transporter engineering in microbial cell factories: the ins, the outs, and the in-betweens.Current opinion in biotechnology · 2020Review
- Multi-Path Optimization for Efficient Production of 2'-Fucosyllactose in an EngineeredFrontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background2'-Fucosyllactose (2-FL), one of the most abundant oligosaccharides in human milk, has potential applications in foods due to its health benefits such as the selective promotion of bifidobacterial growth and the inhibition of pathogenic microbial binding to the human gut. Owing to the limited amounts of 2-FL in human milk, alternative microbial production of 2-FL is considered promising. To date, microbial production of 2-FL has been studied mostly in Escherichia coli. In this study, 2-FL was produced alternatively by using a yeast Saccharomyces cerevisiae, which may have advantages over E. coli.
resultsFucose and lactose were used as the substrates for the salvage pathway which was constructed with fkp coding for a bifunctional enzyme exhibiting L-fucokinase and guanosine 5'-diphosphate-L-fucose phosphorylase activities, fucT2 coding for α-1,2-fucosyltransferase, and LAC12 coding for lactose permease. Production of 2-FL by the resulting engineered yeast was verified by mass spectrometry. 2-FL titers of 92 and 503 mg/L were achieved from 48-h batch fermentation and 120-h fed-batch fermentation fed with ethanol as a carbon source, respectively.
conclusionsThis is the first report on 2-FL production by using yeast S. cerevisiae. These results suggest that S. cerevisiae can be considered as a host engineered for producing 2-FL via the salvage pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.